ABSTRACT
Background Based on the Fukuoka and Kyoto international consensus guidelines, the current clinical management of intraductal papillary mucinous neoplasm (IPMN) largely depends on imaging features. While these criteria are highly sensitive in detecting high-risk IPMN, they lack specificity, resulting in surgical overtreatment. Artificial Intelligence (AI)-based medical image analysis has the potential to augment the clinical management of IPMNs by improving diagnostic accuracy.
Methods Based on a systematic review of the academic literature on AI in IPMN imaging, 1041 publications were identified of which 25 published studies were included in the analysis. The studies were stratified based on prediction target, underlying data type and imaging modality, patient cohort size, and stage of clinical translation and were subsequently analyzed to identify trends and gaps in the field.
Results Research on AI in IPMN imaging has been increasing in recent years. The majority of studies utilized CT imaging to train computational models. Most studies presented computational models developed on single-center datasets (n=11,44%) and included less than 250 patients (n=18,72%). Methodologically, convolutional neural network (CNN)-based algorithms were most commonly used. Thematically, most studies reported models augmenting differential diagnosis (n=9,36%) or risk stratification (n=10,40%) rather than IPMN detection (n=5,20%) or IPMN segmentation (n=2,8%).
Conclusion This systematic review provides a comprehensive overview of the research landscape of AI in IPMN imaging. Computational models have potential to enhance the accurate and precise stratification of patients with IPMN. Multicenter collaboration and datasets comprising various modalities are necessary to fully utilize this potential, alongside concerted efforts towards clinical translation.
Highlights
Artificial Intelligence holds promise in the field of IPMN by augmenting IPMN detection, differentiation of different types of pancreatic cysts, stratifying malignant progression risk, and automating the analysis of IPMN imaging through computational cyst segmentation.
The majority of studies related to AI-based analysis of IPMN imaging use single-center patient cohorts of less than 250 patients to develop and validate computational models and consider imaging as the only data modality.
Reporting transparency of existing studies on AI in IPMN imaging is limited and there remains a scarcity of comprehensive, multimodal approaches as well as clinical translation.
Competing Interest Statement
FRK declares unpaid advisory roles for Perspectum, Inc., Oxford, UK; Radical Healthcare, Inc., San Francisco, CA; and the Surgical Data Science Collective (SDSC), Washington, DC. CMS declares an unpaid advisory role for Perspectum, Inc., Oxford, UK. All other authors declare no competing interests.
Funding Statement
CMS and FRK receive support from the Indiana Clinical and Translational Sciences Institute funded, in part, by Grant Number UM1TR004402 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. Furthermore, FRK receives support from the German Cancer Research Center (CoBot 2.0) and the Joachim Herz Foundation (Add-On Fellowship for Interdisciplinary Life Science). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This systematic review exclusively analyzes previously published studies and does not involve collecting or using any human data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
